Bomyntra®▼

(Denosumab)

For healthcare professionals only. This content contains promotional and brand information.

Scroll down for Bomyntra prescribing information and further product details. For adverse event reporting see bottom of webpage.

 

Bomyntra 120 mg solution for injection in vial. Each vial contains 120 mg of denosumab in 1.7 mL of solution (70 mg/mL).

Bomyntyra 120 mg solution for injection in pre-filled syringe.

Each pre-filled syringe contains 120 mg of denosumab in 1.7 mL of solution (70 mg/mL).

The SmPC and Patient Leaflets are located on the electronic medicines compendium (emc). Note: by clicking the link you will leave the Fresenius Kabi GB website and be directed to the electronic medicines compendium website.

Please note that product images are for illustrative purposes only and labelling on products may appear differently.

Product Image Sizing FK website - bomyntra
Filename
Prescribing Info for Bomyntra.pdf
Size
105 KB
Format
pdf
Prescribing Info for Bomyntra

Details

Below are the therapeutic indications for Bomymtra 120 mg solution for injection in vial and Bomyntra 120 mg solution for injection in pre-filled syringe.

Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone.

Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity.
 

Adverse events should be reported. Reporting forms and information can be found at: https://yellowcard.mhra.gov.uk  Adverse events should also be reported to Fresenius Kabi Ltd. Cestrian Court, Eastgate Way, Manor Park, Runcorn, Cheshire, WA7 1NT 
Tel +44 (0)800 090 2513. Email: pharmacovigilance.gb@fresenius-kabi.com

GB-BOM-2600002 March 2026

By entering the Healthcare Professional Area you are confirming you are a GB Healthcare Professional. This area contains promotional information. If you are not a Healthcare Professional you will be directed to the Fresenius Kabi GB Corporate website.

GB-NP-2400163 October 2024